Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy (Q42910816)
Jump to navigation
Jump to search
scientific article published on 20 August 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy |
scientific article published on 20 August 2015 |
Statements
1 reference
Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy (English)
1 reference
Evangelos Terpos
Marie-Christine Kyrtsonis
Panagiotis Repousis
Evdoxia Hatjiharissi
Amalia Vassou
Sossana Delimpasi
Anastasia Sioni
Elina Vervessou
Michael Voulgarelis
Pierre Morel
Evrydiki Michalis
Costantinos Tsatalas
20 August 2015
1 reference
1 reference
1 reference
1 reference
1 reference